Leiters and Mobius Therapeutics Enter into National Sales and Marketing Agreement for Mitosol

Leiters and Mobius Therapeutics announced that they have entered into a national sales and marketing agreement for Mitosol, the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication.

Leiters, an FDA-registered 503B outsourcing provider of ophthalmology and hospital-based services, has a long history of compounding mitomycin for its customers. However, consistent with its commitment to meet or exceed all FDA regulations, Leiters is unable to compound an essential copy of an approved product, according to a company news release. Therefore, to minimize supply disruption and continue providing outstanding service to its customers, Leiters has entered into a collaboration with Mobius Therapeutics to supply Mitosol. 

Mitosol (mitomycin for solution) 0.2mg/vial is provided as part of a kit for ophthalmic use. The kit contains a 0.2 mg vial of mitomycin-c along with accessories allowing for safe, convenient and compliant acquisition, storage and handling of mitomycin-c.

“We are excited to partner with Mobius Therapeutics to ensure our ophthalmic customers have access to the high-quality medicines they need for their patients,” Robin Smith Hoke, Chief Executive Officer of Leiters, said in a company news release.

“For some time, we have believed that specialty manufacturers like Mobius and outsourcing facilities such as Leiters hold more in common than in contest,” said Ed Timm, CEO of Mobius Therapeutics.  “Leiters’ decision creates two clear winners: patients and providers. We applaud their action and hope that such collaboration will become the norm, rather than the exception.”